Compare BIIB & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | FCNCA |
|---|---|---|
| Founded | 1978 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 22.6B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | FCNCA |
|---|---|---|
| Price | $177.15 | $2,160.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 9 |
| Target Price | $177.40 | ★ $2,115.56 |
| AVG Volume (30 Days) | ★ 2.4M | 82.0K |
| Earning Date | 02-11-2026 | 01-23-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | 10.97 | ★ 169.29 |
| Revenue | ★ $10,065,900,000.00 | $8,897,000,000.00 |
| Revenue This Year | $3.58 | $3.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.14 | ★ $12.88 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $110.04 | $1,473.62 |
| 52 Week High | $185.17 | $2,412.93 |
| Indicator | BIIB | FCNCA |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 75.19 |
| Support Level | $175.00 | $2,085.54 |
| Resistance Level | $177.18 | $2,201.78 |
| Average True Range (ATR) | 4.76 | 40.94 |
| MACD | -0.61 | 5.41 |
| Stochastic Oscillator | 63.96 | 82.24 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through its extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.